Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders Trial
A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 130 participants.
Also called NCT06488105
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose prevention
- Phase
- Phase 2
- Enrolled
- 130 participants
- Sponsor
- Registry
-
NCT06488105
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Recruiting
Technical summary
Registry record NCT06488105. Randomized; no masking; primary purpose prevention. Start 2024-08-05 (actual); primary completion 2027-11-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders Trial
- Acronym
- EMERALD RCT
- Condition
- Lipid Disorder
- Condition
- Hypercholesterolemia
- Condition
- Cardiovascular Diseases
- Condition
- Atherosclerosis
- Intervention (Drug)
- Statin (rosuvastatin 10 or 40 mg daily, depending on risk)
- Intervention (Behavioral)
- Healthy Lifestyle Counseling
- Intervention (Other)
- Outpatient Followup
- Lead sponsor
- Wake Forest University Health Sciences
- Collaborator
- National Institutes of Health (NIH)
- Collaborator
- National Heart, Lung, and Blood Institute (NHLBI)
Record details
- Record id
cardio:ct-nct06488105- Content hash
af750d96293d700417f9bd87cd04f1dfee597532600fe4ed27beebd1ccedbb62